US · Healthcare · Biotechnology
EPS came in at -0.91 against a street estimate of -0.80 — a miss of 13.7%.
Analysts rate Helus Pharma Inc. a strong buy (11 buy, 0 hold, 0 sell out of 11) with an average price target of $41.23.
| Fund | Stake |
|---|---|
| VR Adviser, LLC | 5.27% |
| Orbimed Advisors LLC | 4.48% |
| Adage Capital Partners Gp LLC | 4.19% |
| Millennium Management LLC | 3.60% |
| Rosalind Advisors, Inc. | 2.68% |
| Sphera Funds Management Ltd. | 2.22% |
| DCF Advisers, LLC | 1.96% |
| Sio Capital Management, LLC | 1.78% |
| Document | Date |
|---|---|
| Current report (6-K) · Q3 FY2027 HEADLINE NUMBERS • The document is a Form 6-K filing by Helus Pharma Inc., dated November 3, 2026. • The filing contains one attached exhibit: a ne | 2026-11-03 |
| Current report (6-K) · Q3 FY2027 HEADLINE NUMBERS • The filing contains a news release dated October 27, 2026, but the provided document does not include the release’s operating or f | 2026-10-27 |
| Current report (6-K) · Q3 FY2027 HEADLINE NUMBERS • Helus Pharma’s lead programs are progressing: HLP003 is in Phase 3 for potential adjunctive treatment of major depressive disorder | 2026-10-21 |
| Current report (6-K) · Q3 FY2027 HEADLINE NUMBERS • Helus Pharma appointed Dr. Suresh Durgam to its Board of Directors on October 15, 2026, subject to Cboe Canada approval. • Dr. D | 2026-10-15 |
| Current report (6-K) · Q3 FY2027 OTHER NOTABLE POINTS • This Form 6-K filing from Helus Pharma Inc. is dated October 8, 2026. • The filing contains one exhibit: a news release dated | 2026-10-08 |
| Current report (6-K) · Q3 FY2027 HEADLINE NUMBERS • Helus Pharma Inc. filed a Form 6-K with the U.S. Securities and Exchange Commission on October 5, 2026. • The filing covers the m | 2026-10-05 |
| Current report (6-K) · Q3 FY2027 HEADLINE NUMBERS • Cybin Inc. legally changed its name to Helus Pharma Inc. effective October 1, 2026. • Shareholders approved the name change at th | 2026-10-02 |
| Current report (6-K) · Q3 FY2027 OTHER NOTABLE POINTS • Helus Pharma Inc. filed a Form 6-K with the U.S. Securities and Exchange Commission for October 2026. • The filing was dated | 2026-10-01 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Helus Pharma Inc. — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.